Loading provider…
Loading provider…
Hematology & Oncology Physician in Colorado Springs, CO
NPI: 1679569842Primary Employer
Assurex Health, Inc.
genesight.com
HQ Phone
Get M.D. Philip's Phone Numberphone_androidMobile
Get M.D. Philip's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
FL State Medical License
2022 - 2027
KY State Medical License
1997 - 2026
MD State Medical License
1981 - 2026
OH State Medical License
1977 - 2026

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
University Of Louisville School Of Medicine
louisville.edu
Medical School
Until 1975
NIH Clinical Center
Residency • CANCER RESEARCH - CLINICAL ASSOCIATE
1981 - 1983
University of Cincinnati Medical Center/College of Medicine
Fellowship • Hematology and Medical Oncology
1980 - 1981
Residency • Internal Medicine
1975 - 1979
Authors: Igor Puzanov, Harriet Kluger, Mario Sznol, Jeffrey Sosman, Richard Carvajal, William Sharfman, Donald Lawrence, Anna Chien, David Mcdermott, Evan Lipson, Frank Hodi, Suzanne Topalian
Journal: J Clin Oncol
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Authors: Rebecca Heist, Mary Pinder-Schenck, David Jackman, Mario Sznol, Jeffrey Sosman, Richard Carvajal, David Carbone, Lecia Sequist, Naiyer Rizvi, David Mcdermott, Matthew Hellmann, David Spigel, Suzanne Topalian
Publication Date: 2015-04-22
Lead Sponsor: GRAIL, Inc.
Lead Sponsor: BioNTech US Inc.
Collaborators: Apexigen America, Inc.
Intervention / Treatment: BIOLOGICAL: Nivolumab, OTHER: Adjuvant, BIOLOGICAL: ipilimumab, BIOLOGICAL: NEO-PV-01, BIOLOGICAL: APX005M
Lead Sponsor: Oncternal Therapeutics, Inc
Collaborators: University of California, San Diego, California Institute for Regenerative Medicine (CIRM), Pharmacyclics LLC.
Intervention / Treatment: DRUG: Ibrutinib alone, DRUG: Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, DRUG: Cirmtuzumab (300mg) plus Ibrutinib, DRUG: Cirmtuzumab (600 mg) plus ibrutinib, DRUG: Cirmtuzumab (RDR) plus ibrutinib, DRUG: Cirmtuzumab plus ibrutinib